JPWO2022214691A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022214691A5 JPWO2022214691A5 JP2023561906A JP2023561906A JPWO2022214691A5 JP WO2022214691 A5 JPWO2022214691 A5 JP WO2022214691A5 JP 2023561906 A JP2023561906 A JP 2023561906A JP 2023561906 A JP2023561906 A JP 2023561906A JP WO2022214691 A5 JPWO2022214691 A5 JP WO2022214691A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- halo
- independently selected
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052805 deuterium Inorganic materials 0.000 claims 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000233872 Pneumocystis carinii Species 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167690 | 2021-04-09 | ||
| EP21167690.3 | 2021-04-09 | ||
| EP21181134 | 2021-06-23 | ||
| EP21181134.4 | 2021-06-23 | ||
| PCT/EP2022/059527 WO2022214691A1 (en) | 2021-04-09 | 2022-04-08 | Deuterated dhodh inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515062A JP2024515062A (ja) | 2024-04-04 |
| JPWO2022214691A5 true JPWO2022214691A5 (https=) | 2025-04-15 |
| JP2024515062A5 JP2024515062A5 (https=) | 2025-04-15 |
Family
ID=81585846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561906A Pending JP2024515062A (ja) | 2021-04-09 | 2022-04-08 | 重水素化ｄｈｏｄｈ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240199535A1 (https=) |
| EP (1) | EP4320100A1 (https=) |
| JP (1) | JP2024515062A (https=) |
| KR (1) | KR20240007144A (https=) |
| AU (1) | AU2022253683A1 (https=) |
| BR (1) | BR112023020806A2 (https=) |
| CA (1) | CA3215002A1 (https=) |
| IL (1) | IL307559A (https=) |
| MX (1) | MX2023011864A (https=) |
| WO (1) | WO2022214691A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3139914T3 (pl) | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| ES2972099T3 (es) | 2018-03-09 | 2024-06-11 | Kiora Pharmaceuticals Gmbh | Formulación oftálmica |
| WO2023172818A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
| TW202444688A (zh) | 2023-03-29 | 2024-11-16 | 德商埃慕尼克股份公司 | 作為nurr1激動劑之維多氟地莫(vidofludimus)及相關結構 |
| TW202506107A (zh) | 2023-06-28 | 2025-02-16 | 德商埃慕尼克股份公司 | 雜芳族dhodh抑制劑 |
| WO2025215126A1 (en) | 2024-04-12 | 2025-10-16 | Immunic Ag | Synthesis of vidofludimus and its calcium salt |
| WO2026074007A1 (en) | 2024-10-02 | 2026-04-09 | Immunic Ag | Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| EP1581478A1 (en) | 2002-12-23 | 2005-10-05 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| MXPA05006890A (es) | 2002-12-23 | 2006-04-07 | 4Sc Ag | Compuestos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. |
| DK2050749T3 (en) | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| WO2009140279A2 (en) | 2008-05-12 | 2009-11-19 | Concert Pharmaceuticals, Inc. | Sulfonyl urea compounds |
| CN102271674A (zh) | 2008-11-07 | 2011-12-07 | 4Sc股份公司 | 用于治疗自身免疫病的包含dhodh抑制剂和氨甲喋呤的联合治疗 |
| TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| UA108760C2 (uk) | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
| KR102265277B1 (ko) * | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
| PL3139914T3 (pl) | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| WO2016045587A1 (zh) | 2014-09-26 | 2016-03-31 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| WO2018177151A1 (en) * | 2017-03-28 | 2018-10-04 | Xiamen University | Compounds modulating activity of farnesoid x receptor and methods for the use thereof |
| CN111343975A (zh) | 2017-11-23 | 2020-06-26 | 埃慕尼克股份公司 | 用于预防或治疗慢性炎性疾病和/或自身免疫疾病的维多地莫的剂量方案 |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| ES2972099T3 (es) | 2018-03-09 | 2024-06-11 | Kiora Pharmaceuticals Gmbh | Formulación oftálmica |
| WO2019175396A1 (en) | 2018-03-16 | 2019-09-19 | Immunic Ag | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
-
2022
- 2022-04-08 MX MX2023011864A patent/MX2023011864A/es unknown
- 2022-04-08 KR KR1020237038184A patent/KR20240007144A/ko active Pending
- 2022-04-08 IL IL307559A patent/IL307559A/en unknown
- 2022-04-08 JP JP2023561906A patent/JP2024515062A/ja active Pending
- 2022-04-08 WO PCT/EP2022/059527 patent/WO2022214691A1/en not_active Ceased
- 2022-04-08 BR BR112023020806A patent/BR112023020806A2/pt unknown
- 2022-04-08 US US18/554,365 patent/US20240199535A1/en active Pending
- 2022-04-08 AU AU2022253683A patent/AU2022253683A1/en active Pending
- 2022-04-08 EP EP22721769.2A patent/EP4320100A1/en active Pending
- 2022-04-08 CA CA3215002A patent/CA3215002A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4129286B2 (ja) | 新規チアゾリジン−４−オン誘導体 | |
| JP2022506685A5 (https=) | ||
| JP2010540508A5 (https=) | ||
| CA2662517A1 (en) | Treatment of cancer | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| JP2019510787A5 (https=) | ||
| JP2019527682A5 (https=) | ||
| JP2013510825A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| JP2017519754A5 (https=) | ||
| JPWO2022214691A5 (https=) | ||
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| JPWO2022251502A5 (https=) | ||
| JP2007505044A5 (https=) | ||
| TW201641492A (zh) | 經取代1,2,3-三唑、其用途、以及包含其之醫藥組成物 | |
| JPH04221327A (ja) | スクアレンエポキシダーゼの抑制剤としてのスクアレンのジ−及びテトラ−フルオロ類似体類 | |
| JP2021514399A5 (https=) | ||
| JPWO2020097258A5 (https=) | ||
| JPH07504666A (ja) | プリン類似化合物の抗ウイルス性ホスホン酸誘導体 | |
| JPWO2023118576A5 (https=) | ||
| JPWO2021207530A5 (https=) | ||
| JP2004505951A5 (https=) | ||
| JPWO2023066283A5 (https=) | ||
| JPWO2021231726A5 (https=) |